NYX 104
Alternative Names: NYX-104Latest Information Update: 28 May 2022
At a glance
- Originator Noxopharm
- Developer Noxopharm; Nyrada
- Class Neuroprotectants
- Mechanism of Action TRPC3 cation channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Neurological-disorders in Australia (Rectal, Suppository)
- 11 May 2018 NYX 104 is available for licensing as of 27 Jan 2018. http://www.nyrada.com
- 11 May 2018 Nyrada has patent protection for NYX 104